Beyond Organ-Specific Therapies: A Unified Approach to Multi-Organ Fibrosis

Area of Science:

• Fibrosis research
• Multi-organ pathology
• Drug development

Background:

• Organ fibrosis, excessive tissue scarring in liver, kidney, lung, and heart, presents a significant global health challenge with high morbidity and mortality.
• Current research and therapeutic strategies often focus on individual organs, limiting comprehensive treatment approaches.
• A lack of effective antifibrotic treatments necessitates a broader understanding of fibrogenesis.

Purpose of the Study:

• To provide a comprehensive review of multi-organ fibrosis, integrating insights from liver, kidney, lung, and heart.
• To elucidate the complex cellular and molecular mechanisms underlying fibrogenesis across different organs.
• To explore current and future antifibrotic therapies, including novel pan-organ drug development.

Main Methods:

• Literature review of recent advances in organ fibrosis research.
• Analysis of common and organ-specific factors driving fibrogenesis.
• Examination of existing and emerging antifibrotic therapeutic strategies.

Main Results:

• Recent advances have clarified complex cellular and molecular mechanisms in liver, kidney, lung, and heart fibrosis.
• Both shared and distinct fibrotic drivers exist across different organs.
• Innovative approaches for pan-organ antifibrotic drug development are emerging.

Conclusions:

• Understanding multi-organ fibrosis requires a holistic approach, considering shared and unique mechanisms.
• Developing pan-organ antifibrotic therapies holds promise for treating widespread fibrotic diseases.
• Future clinical trial designs must address the complexities of multi-organ fibrotic conditions.